Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 1

1(25.0%)

Phase 2

1(25.0%)

4Total

N/A(2)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05173727Completed

Prevalence and Serotype of Streptococcus Pneumoniae Hospitalized Adult With Community-Acquired Pneumonia

Role: collaborator

NCT05444790Completed

Abbott NxTekTM Malaria RDT WHO Prequalification Study

Role: collaborator

NCT05085301Completed

RapiGEN BIOCREDIT Malaria Ag RDTs WHO Prequalification Study

Role: collaborator

NCT04223674Not ApplicableUnknown

Serological Screen and Treat Trial for Plasmodium Vivax

Role: collaborator

NCT04873414Phase 2Unknown

Convalescent Plasma as Adjunct Therapy for COVID-19

Role: collaborator

NCT04407208Phase 1Completed

Convalescent Plasma Therapy in Patients With COVID-19

Role: collaborator

NCT02001428Not ApplicableCompleted

Malaria in Early Life Study

Role: collaborator

NCT02353494Completed

Efficacy and Safety of Dihydroartemisinin-piperaquine (DHP) for the Treatment of Uncomplicated Malaria

Role: collaborator

NCT02104518Completed

Evaluation of Different G6PD Testing Platforms

Role: collaborator

All 9 trials loaded